Tristel (TSNLF) Price & Analysis

Q: What was Tristel plc’s price range in the past 12 months?

Tristel plc lowest stock price was $3.24 and its highest was $6.37 in the past 12 months.

Q: What is Tristel plc’s market cap?

Tristel plc’s market cap is $288.58M.

Q: When is Tristel plc’s upcoming earnings report date?

Tristel plc’s upcoming earnings report date is Oct 19, 2026 which is in 84 days.

Q: How were Tristel plc’s earnings last quarter?

Tristel plc released its earnings results on Mar 02, 2026. The company reported $0.126 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.003.

Q: Is Tristel plc overvalued?

According to Wall Street analysts Tristel plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Tristel plc pay dividends?

Tristel plc pays a Semiannually dividend of $0.076 which represents an annual dividend yield of 3.14%. See more information on Tristel plc dividends here

Q: What is Tristel plc’s EPS estimate?

Tristel plc’s EPS estimate is 0.11.

Q: What happened to Tristel plc’s price movement after its last earnings report?

Tristel plc reported an EPS of $0.126 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went same 0%.

Q: Which hedge fund is a major shareholder of Tristel plc?

Currently, no hedge funds are holding shares in TSNLF

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

0 Followers

TSNLF Stock Chart & Stats

$6.00

$0.72(13.64%)

Jul 24, 2026

―

Day’s Range― - ―

52-Week Range$3.24 - $6.37

Previous CloseN/A

VolumeN/A

Average Volume (3M)3.00

Market Cap

$288.58M

Enterprise Value$196.48

Total Cash (Recent Filing)$13.29M

Total Debt (Recent Filing)$5.82M

Price to Earnings (P/E)27.3

Beta0.27

Next Earnings

Oct 19, 2026

EPS Estimate

0.11

Next Dividend Ex-DateN/A

Dividend Yield3.14%

Share Statistics

EPS (TTM)0.16

Shares OutstandingN/A

10 Day Avg. Volume10

30 Day Avg. Volume3

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)5.93

Price to Sales (P/S)4.21

P/FCF Ratio20.67

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)<0.01

Revenue Forecast (FY)$753.47K

Bulls Say, Bears Say

Bulls Say

High And Sustainable ProfitabilityVery high gross margins and healthy net margins indicate durable pricing power and product economics in infection‑prevention consumables. Strong margins support reinvestment in clinical trials, commercial rollouts and a progressive dividend policy while insulating returns from moderate volume swings.

Strong Balance Sheet And LiquidityA debt‑free position, material cash buffer and low leverage give Tristel flexibility to fund commercial expansion, insourcing investments and clinical programmes without risking solvency. The strong equity base reduces refinancing risk and supports continued dividend policy and targeted hires.

Recurring Consumables Model And U.S. Commercial MomentumThe core recurring consumables model creates dependable revenue tied to procedure volumes; expanding U.S. sales, product launches and distributor/OEM agreements materially increase addressable market and scale economics, supporting long‑term revenue visibility and cross‑sell opportunities.

Bears Say

APAC And China Demand WeaknessSustained weakness in China/APAC compresses a sizable growth runway and reflects structural risks—customer bankruptcies and healthcare financing shifts—that can reduce adoption and tender success. Regional underperformance may offset gains elsewhere for several quarters.

Declining Free Cash Flow GrowthA meaningful drop in free cash flow growth reduces internal funding capacity for clinical programmes, U.S. scaling and insourcing costs. If the trend persists it could force slower expansion, higher external financing or constrain the progressive dividend despite strong operating cash conversion historically.

Higher Operating Spend And Recruitment RisksElevated operating costs from insourcing, hiring and transition expenses can compress margins before benefits materialise. Slower recruitment of commercial talent risks delaying U.S. revenue scale, extending the payback on clinical and commercial investments and pressuring near‑term profitability.

Tristel News

Tristel launches premium paid tier of 3T compliance platform

The latest announcement is out from Tristel ( ($GB:TSTL) ). Tristel plc, a specialist in infection prevention solutions...

12h ago

Tristel posts double‑digit growth and boosts cash ahead of new CEO arrival

An update from Tristel ( ($GB:TSTL) ) is now available. Tristel has reported another year of strong trading,...

6d ago

Tristel deepens U.S. infection prevention footprint with APIC showcase and new digital offering

Tristel ( ($GB:TSTL) ) has provided an update. Tristel plc highlighted growing clinical engagement in the U.S. after...

21d ago

Tristel Names Medical Technology Veteran Chris Lee as New CEO to Drive Global Growth

Tristel ( ($GB:TSTL) ) has shared an update. Tristel, a specialist in infection prevention products for medical devices...

1M ago

Tristel Updates Share Capital After Employee Option Exercise

Tristel ( ($GB:TSTL) ) just unveiled an announcement. Tristel plc, a specialist in chlorine dioxide-based infection prevention products...

2M ago

Tristel Increases Share Capital After Employee Option Exercise

Tristel ( ($GB:TSTL) ) just unveiled an update. Tristel plc, the AIM‑quoted manufacturer of infection prevention products for...

3M ago

Tristel Updates Share Capital After Employee Option Exercise

Tristel ( ($GB:TSTL) ) has issued an announcement. Tristel has issued and allotted 20,000 new ordinary shares following...

3M ago

Artemis Takes 3% Stake in Infection Prevention Group Tristel

Tristel ( ($GB:TSTL) ) just unveiled an announcement. Tristel plc, a UK-based infection prevention specialist, develops and manufactures...

3M ago

Tristel Non-Executive Director Increases Stake in Infection Prevention Group

An update from Tristel ( ($GB:TSTL) ) is now available. Tristel plc, the AIM-listed infection prevention specialist, has...

4M ago

Tristel to Outline Strategy at ShareSoc Growth Event in Leeds

An announcement from Tristel ( ($GB:TSTL) ) is now available. Tristel plc, the AIM-listed infection prevention company headquartered...

4M ago

TSNLF FAQ

What was Tristel plc’s price range in the past 12 months?

Tristel plc lowest stock price was $3.24 and its highest was $6.37 in the past 12 months.

What is Tristel plc’s market cap?

Tristel plc’s market cap is $288.58M.

When is Tristel plc’s upcoming earnings report date?

Tristel plc’s upcoming earnings report date is Oct 19, 2026 which is in 84 days.

How were Tristel plc’s earnings last quarter?

Tristel plc released its earnings results on Mar 02, 2026. The company reported $0.126 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.003.

Is Tristel plc overvalued?

According to Wall Street analysts Tristel plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tristel plc pay dividends?

Tristel plc pays a Semiannually dividend of $0.076 which represents an annual dividend yield of 3.14%. See more information on Tristel plc dividends here

What is Tristel plc’s EPS estimate?

Tristel plc’s EPS estimate is 0.11.

How many shares outstanding does Tristel plc have?

Currently, no data Available

What happened to Tristel plc’s price movement after its last earnings report?

Tristel plc reported an EPS of $0.126 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Tristel plc?

Currently, no hedge funds are holding shares in TSNLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Tristel Stock Smart Score

Neutral

Fundamentals

Return on Equity

3.14%

Trailing 12-Months

Asset Growth

6.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tristel plc

Tristel plc is a company specializing in the creation, production, and global distribution of products designed to prevent infections, serving both its home market in the UK and international clients. Its operations are structured around three core divisions: the decontamination of medical devices within hospital environments, the disinfection of hospital-based environmental surfaces, and an additional 'Other' category. The firm offers an extensive range of disinfection solutions for medical instruments under its Tristel brand. These solutions are applied across a wide spectrum of clinical areas, including airway management, cardiology, ear, nose and throat (ENT), endoscopy, gastrointestinal physiology, laboratory applications, ophthalmology, phlebotomy, reproductive health/IVF, general surface disinfection, ultrasound, urology, and women's health, alongside other specialized products. Tristel plc was established in 1993 and has its main office situated in Snailwell, United Kingdom.